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Metabolomics studies hold promise for the discovery of pathways linked to disease processes. Cardiovascular disease
(CVD) represents the leading cause of death and morbidity worldwide. Here we used a metabolomics approach to
generate unbiased small-molecule metabolic profiles in plasma that predict risk for CVD. Three metabolites of the
dietary lipid phosphatidylcholine—choline, trimethylamine N-oxide (TMAO) and betaine—were identified and then
shown to predict risk for CVD in an independent large clinical cohort. Dietary supplementation of mice with choline,
TMAO or betaine promoted upregulation of multiple macrophage scavenger receptors linked to atherosclerosis, and
supplementationwith choline or TMAOpromoted atherosclerosis. Studies using germ-freemice confirmed a critical role
for dietary choline and gut flora in TMAO production, augmented macrophage cholesterol accumulation and foam cell
formation. Suppression of intestinal microflora in atherosclerosis-prone mice inhibited dietary-choline-enhanced
atherosclerosis. Genetic variations controlling expression of flavin monooxygenases, an enzymatic source of TMAO,
segregated with atherosclerosis in hyperlipidaemic mice. Discovery of a relationship between gut-flora-dependent
metabolism of dietary phosphatidylcholine and CVD pathogenesis provides opportunities for the development of new
diagnostic tests and therapeutic approaches for atherosclerotic heart disease.
The pathogenesis of CVD includes genetic and environmental factors.
A known environmental risk factor for the development of CVD is a
diet rich in lipids. A relationship between blood cholesterol and
triglyceride levels and cardiovascular risk is well established.
However, less is known about the role of the third major category
of lipids, phospholipids, in atherosclerotic heart disease pathogenesis.
Another potential yet controversial environmental factor in the
development or progression of atherosclerotic heart disease is inflam
mation due to infectious agents. Some studies have reported associa
tions between coronary disease and pathogens such as cytomegalovirus
(CMV), Helicobactor pylori, and Chlamydia pneumoniae1 4. However,
prospective randomized trials with antibiotics in humans have thus far
failed to demonstrate cardiovascular benefit5 7 and studies with germ
free hyperlipidaemic mice confirm that infectious agents are not
necessary for murine atherosclerotic plaque development8. Although
a definite cause and effect relationship between a bacterial or viral
pathogen and atherosclerosis in humans has not yet been established,
the prospect of a role for microbes in atherosclerosis susceptibility
remains enticing.
The intestinal microbiota (‘gut flora’), comprised of trillions of typ
ically non pathogenic commensal organisms, serve as a filter for our
greatest environmental exposure whatweeat.Gut florahaveanessen
tial role, aiding in the digestion and absorption of many nutrients9.
Animal studies have recently shown that intestinal microbial com
munities can influence the efficiency of harvesting energy from diet,
and consequently influence susceptibility to obesity10. Metabolomics
studies of inbredmouse strains have also recently shown that gutmicro
biota may have an active role in the development of complexmetabolic
abnormalities, such as susceptibility to insulin resistance and non
alcoholic fatty liver disease11. A link between gut flora dependent
phospholipid metabolism and atherosclerosis risk through generation
of pro atherosclerotic metabolites has not yet been reported.
Metabolomics studies identify markers of CVD
In initial studies we sought to discover unbiased small molecule meta
bolic profiles in plasma that predict increased risk for CVD. An initial
‘Learning Cohort’ was used comprising plasma from stable patients
undergoing elective cardiac evaluation who subsequently experienced
a heart attack (myocardial infarction), stroke or death over the ensuing
three year period versus age and gender matched subjects who did
not. Liquid chromatography with on line mass spectrometry (LC/
MS) analysis of plasma was performed to define analytes associated
with cardiac risk as described inMethods. Of an initial 2,0001 analytes
monitored, 40met all acceptability criteria within the Learning Cohort.
Subsequent studies within an independent ‘Validation Cohort’ led to
identification of 18 analytes that met acceptability criteria in both
Learning and Validation Cohorts (Fig. 1a, b, Supplementary Fig. 1a
and Supplementary Table 1).
The structural identity of the 18 small molecules in plasma, the
levels of which track with cardiac risks, was not known, as the com
pounds were screened on the basis of retention time and mass to
charge ratio (m/z) when analysed by LC/MS. Among the 18 analytes,
those withm/z 76, 104 and 118 demonstrated significant (P, 0.001)
correlations among one another, suggesting a potential relationship
via a common biochemical pathway (Supplementary Fig. 1b). We
therefore initially sought to structurally define these three analytes.
Phosphatidylcholine metabolites are linked to CVD
The candidate compound in plasma with anm/z of 76 associated with
CVD risks was isolated and unambiguously identified as TMAOusing

used as isotope tracer for feeding studies. When mice were fed
through oral gavage with d9 PC, the time dependent appearance of
the anticipated d9 isotopomer of TMAO was observed in plasma
(Fig. 2c). Interestingly, pre treatment of mice with a three week
course of broad spectrum antibiotics to suppress intestinal flora com
pletely suppressed the appearance of d9 TMAO in plasma after oral
d9 PC administration (Fig. 2c). A similar pattern was observed after
oral administration of d9 choline to mice, with d9 TMAO produced
in untreated mice, but not in the same mice after a 3 week course of
broad spectrum antibiotics (Supplementary Fig. 7b), or in germ free
mice born sterilely by Caesarean section (Supplementary Fig. 7c). In a
final series of studies, mice with suppressed intestinal microflora after
antibiotics were placed in conventional cages with normal (non
germ free) mice to permit intestinal colonization with microbes.
After four weeks, repeat oral d9 PC challenge of the now ‘conventio
nalized’ mice resulted in readily detectable plasma levels of d9 TMAO
(Fig. 2c). Similar results were observed after conventionalization of
germ free mice and oral d9 choline (Supplementary Fig. 7c).
Collectively, these results show an obligate role for intestinal micro
biota in the generation of TMAO from the dietary lipid PC. They also
reveal the following metabolic pathway for dietary PC producing
TMAO: PCR cholineRTMARTMAO.
Dietary PC metabolites predict CVD risk
We next sought to independently confirm the prognostic value of
monitoring fasting plasma levels of TMAO, choline and betaine in a
large independent clinical cohort distinct from subjects examined in
both the Learning and Validation Cohorts. Stable subjects (N 1,876)
undergoing elective cardiac evaluations were enrolled. Clinical, demo
graphic and laboratory characteristics of the cohort are provided in
Supplementary Table 4a. Fasting plasma levels of TMAO, choline and
betaine were quantified by LC/MS/MS usingmethods specific for each
analyte (Supplementary Fig. 8). Increasing levels of choline, TMAO
and betaine were all observed to show dose dependent associations
with the presence of CVD (Fig. 3a c) and multiple individual CVD
phenotypes including peripheral artery disease (PAD), coronary artery
disease (CAD), and history of myocardial infarction (see Supplemen
tary Table 5a d for multilogistic regression models, and Supplemen
tary Table 5e for Somers’ Dxy correlation). The associations between
increased risk of all CVDphenotypesmonitored and elevated systemic
levels of the three PC metabolites held true after adjustments for tra
ditional cardiac risk factors and medication usage (Fig. 3a c and
Supplementary Table 5a e).
Dietary choline or TMAO promotes atherosclerosis
We next investigated whether the strong associations noted between
plasma levels of the dietaryPCmetabolites andCVDrisk reflected some
hidden underlying pro atherosclerotic mechanism. Atherosclerosis
prone mice (C57BL/6J Apoe / ) at time of weaning were placed on
either normal chow diet (contains 0.08 0.09% total choline, wt/wt) or
normal chow diet supplemented with intermediate (0.5%) or high
amounts of additional choline (1.0%) or TMAO (0.12%). At 20 weeks
of age increased total aortic root atherosclerotic plaque area was noted
inbothmale and femalemice ondiets supplementedwith either choline
or TMAO (Fig. 3d and Supplementary Fig. 9a). Analysis of plasma
levels of choline and TMAO in each of the dietary arms showed
nominal changes in plasma levels of choline, but significant increases
of TMAO inmice receiving either choline or TMAO supplementation
(Supplementary Fig. 10). Parallel examination of plasma cholesterol,
triglycerides, lipoproteins, glucose levels andhepatic triglyceride content
in the mice failed to show significant increases that could account for
the enhanced atherosclerosis (Supplementary Table 6 and Supplemen
tary Fig. 11). Interestingly, all dietary groups of mice revealed a sig
nificant positive correlation between plasma levels of TMAO and
atherosclerotic plaque size (Fig. 3e and Supplementary Fig. 9b). Of
note, plasma TMAO levels observed within the female mice (which
get enhanced atherosclerosis relative to their male counterparts), even
on normal chow diet, were significantly higher than those observed
among male mice (Supplementary Fig. 10). No significant gender dif
ferences in plasma levels of TMAO were observed in humans
(P 0.47); however, a clear dose response relationship was observed
between TMAO levels and clinical atherosclerotic plaque burden in
subjects undergoing coronary angiography (Fig. 3f).
Hepatic FMOs, TMAO and atherosclerosis
Hepatic FMO3 is a known enzymatic source for TMAO in humans,
based on the recent recognition of the aetiology of an uncommon
genetic disorder called trimethylaminuria (also known as fish malo
dour syndrome)15,17. Subjects with this metabolic condition have
impaired capacity to convert TMA, which smells like rotting fish, into
TMAO, an odourless stable oxidation product17. We therefore sought
to identify possible sources of genetic regulation and the role of Fmo3
in atherosclerosis using integrative genetics in mice18. Expression
levels of Fmo3 were determined by microarray analysis in the livers
of mice from an F2 intercross between atherosclerosis prone C57BL/
6J Apoe / mice and atherosclerosis resistant C3H/HeJ Apoe /
mice and compared with quantitative measures of atherosclerosis.
The expression level of Fmo3 showed marked differences between
genders (females .1,000 fold higher than in males). Significant
positive correlations were readily found between hepatic Fmo3 expres
sion and atherosclerotic lesions (Fig. 4a, Supplementary Fig. 12, top
row, and Supplementary Fig. 13). Interestingly, a highly significant
negative correlation with plasma high density lipoprotein (HDL) cho
lesterol levels was noted in both male and female mice (Fig. 4b and
Supplementary Fig. 12, middle row). Further, plasma levels of the PC
metabolite TMAOshowed a significant positive correlationwith hepatic
Fmo3 expression level in mice (Fig. 4c and Supplementary Fig. 12,
bottom row).
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Figure 3 | Plasma levels of choline, TMAO and betaine are associated with
atherosclerosis risks in humans and promote atherosclerosis in mice.
a c, Spline models of the logistic regression analyses reflecting risk of CVD
(with 95% CI) according to plasma levels of choline, TMAO and betaine in the
entire cohort (n5 1,876 subjects). d, Comparison in aortic lesion area among
20 week old female C57BL/6JApoe / mice fed with chow diet supplemented
with the indicated amounts (wt/wt) of choline or TMAO from time of weaning
(4 weeks). e, Relationship between plasma TMAO levels and aortic lesion area.
f, Relationship between fasting plasma levels of TMAO versus CAD burden
among subjects (N5 1,020). Boxes represent 25th, 50th and 75th percentile,
and whiskers 5th and 95th percentile plasma levels. Single, double and triple
coronary vessel disease refers to number of major coronary vessels
demonstrating$50% stenosis on diagnostic coronary angiography.
FMO3 is one member of a family of FMO enzymes, the majority of
which are physically located as a cluster of genes on chromosome 1 in
both humans and mice. The various FMOs share sequence homology
and overlapping substrate specificities. Further, although raremutations
in or near the FMO3 gene have been identified in individuals with
trimethylaminuria19, the impact of thesemutations onother FMO genes
remains unknown. Examination of the hepatic expression levels of the
various FMO genes revealed that many are highly correlated with each
other in both mice and humans (Supplementary Table 7). Examination
of hepatic expression levels of additional Fmo genes in mice from the
atherosclerosis F2 intercross revealed that multiple Fmo genes are
significantly correlated with aortic lesion formation, HDL cholesterol
concentrations and plasma TMAO levels (Supplementary Figs 14 16),
suggesting that several members of the FMO family of enzymes may
participate in atherosclerosis and the PCRTMAOmetabolic pathway.
To explore the relationship between hepatic FMOs and plasma TMAO
levels in humans, paired samples of liver and plasma from subjects
undergoing elective liver biopsy were examined. Among all of the
humanFMO genesmonitored, only a trend towards positive association
was noted between hepatic expression of FMO3 and plasma TMAO
levels (Fig. 4d and Supplementary Fig. 17).
Next, we focused on the genetic regulation of hepatic Fmo3 expres
sion (and other Fmo genes) using expression quantitative trait locus
(eQTL) analyses in the F2 mouse intercross. The eQTL plot for Fmo3
messenger RNA levels is shown in Supplementary Fig. 18, and demon
strates a strongly suggestive cis locus (lod score 5.9) onmouse chro
mosome 1 at 151Mb. Fmo3 (and several other Fmo genes) is located at
164.8 Mb in a region identified as non identical by descent between
C3H/HeJ and C57BL/6 (http://mouse.cs.ucla.edu/perlegen/). This
region is just distal to the 95% confidence interval of a previously
reported murine atherosclerosis susceptibility locus20. Examining the
effect of the closest single nucleotide polymorphism (SNP) to Fmo3
(rs3689151) as a functionof alleles inherited fromeither parental strain
indicated a strong effect on atherosclerosis in both genders of the F2
mice (Kruskal Wallis test,P, 1.03 10 6). Bonferroni corrected pair
wise comparisons indicated a dose dependent significant increase in
atherosclerosis in F2 mice heterozygous or homozygous for the
C57BL/6J allele (Fig. 4e). Although the resolution on average for an
F2 intercross of this size is in excess of 20Mb and thus does not provide
‘gene level’ resolution, these data show that the locus encompas
sing the Fmo gene cluster on chromosome 1 is associated with athero
sclerotic lesion size. Collectively, these results indicate that: (1) hepatic
expression levels of multiple Fmo genes are linked to plasma TMAO
levels in mice; (2) hepatic expression levels of multiple Fmo genes are
associated with both the extent of aortic atherosclerosis and HDL
cholesterol levels in mice; (3) hepatic expression levels of FMO3 indi
cate an association with plasma TMAO levels in humans; and (4) a
genetic locus containing the Fmo gene cluster on chromosome 1 in
mice has a strong effect on atherosclerosis.
Diet and gut flora alter macrophage phenotype
To explore potentialmechanisms throughwhich dietary choline and its
metabolites might exert their pro atherosclerotic effects, C57BL/6J
Apoe / mice at time of weaning were placed on a normal chow diet
supplemented with either choline, TMAO or betaine (for .3 weeks).
Both mRNA levels (Supplementary Fig. 19) and surface protein levels
(Fig. 4f, g and Supplementary Fig. 20) of two macrophage scavenger
receptors implicated in atherosclerosis, CD36 and SR A1, were then
determined in peritoneal macrophages. Relative to normal chow diet,
mice supplemented with either choline, TMAO or betaine all showed
enhanced macrophage levels of CD36 and SR A1. We next examined
the impact of dietary choline and gut flora on endogenous formation of
cholesterol laden macrophage foam cells, one of the earliest cellular
hallmarks of the atherosclerotic process. Hyperlipidaemic C57BL/6J
Apoe / mice were fed diets with defined levels of choline as follows:
(1) ‘control’ (0.07 0.08%,wt/wt),which is similar to the choline content
of normal chow (0.08 0.09%); versus (2) high ‘choline’, corresponding
to a.10 fold higher level of choline (1.0%, wt/wt) than normal chow.
Concomitantly, half of the mice were administered broad spectrum
antibiotics for 3 weeks to suppress intestinal microflora, which was
confirmed by the reduction of plasma TMAO levels by .100 fold
(plasma TMAO concentrations in groups receiving antibiotics were
,100nM). Whereas mice on the control diet showedmodest evidence
of endogenous macrophage foam cell formation, as indicated by Oil
red O staining of peritoneal macrophages, mice on the 1% choline
supplemented diet showed markedly enhanced lipid laden macro
phage development (Fig. 5a). In contrast, suppression of intestinal flora
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Figure 4 | Hepatic Fmo genes are linked to atherosclerosis and dietary PC
metabolites enhance macrophage scavenger receptor expression.
a c, Correlation between hepatic Fmo3 expression and aortic lesion, plasma
HDL cholesterol and TMAO in female mice from the F2 intercross between
atherosclerosis prone C57BL/6J Apoe / and atherosclerosis resistant C3H/
HeJ Apoe / mice. d, Correlation between human hepatic FMO3 expression
andplasmaTMAO. e, Effect ofFmo3 genotype (SNP rs3689151) on aortic sinus
atherosclerosis in male mice from the C57BL6/J Apoe / and C3H/HeJ
Apoe / F2 intercross. f, g, Quantification of scavenger receptor CD36 and SR
A1 surface protein levels in macrophages harvested from C57BL/6J mice (13
week) after three weeks of standard chow versus chow supplemented with the
indicated amounts (wt/wt) of choline, TMAO or betaine. Data are presented as
mean6 s.e. from the indicated numbers of mice in each group.
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METHODS
General procedures. Lipids were extracted by chloroform:methanol (2:1, v/v)40.
Cholesterolwasquantified byGC/MS41. Triglyceridewas quantified byGPOreagent
set (Pointe Scientific)42. Cell DNA content was quantified by PicoGreen43. RNAwas
isolated by TRIZOL reagent (Invitrogen) and RNeasy Mini Kit (Qiagen). All
reagents were purchased from Sigma unless otherwise specified.
Research subjects. Plasma samples and associated clinical data were collected as
part of two studies involving stable non symptomatic subjects undergoing elec
tive cardiac evaluations at a tertiary care centre. The first study, GeneBank, is a
large well characterized tissue repository with longitudinal data from subjects
undergoing elective diagnostic left heart catheterization or elective coronary
computed tomography angiography44. The second study, BioBank, includes sub
jects undergoing cardiac risk factor evaluation/modification in a preventive car
diology clinic45. CAD included adjudicated diagnoses of stable or unstable angina,
myocardial infarction or angiographic evidence of$50% stenosis of one or more
epicardial vessels. PAD was defined as any evidence of extra coronary athero
sclerosis. Atherosclerotic CVD was defined as the presence of either CAD or
PAD. All subjects gave written informed consent and the Institutional Review
Board of the Cleveland Clinic approved all study protocols.
Discovery metabolomics analyses began with an unbiased search for plasma
(fasting, EDTA purple top tube) analytes linked to CVD risk using a case control
design (Learning Cohort, N 50 cases and 50 controls). Cases were randomly
selected fromGeneBank subjects who experienced amyocardial infarction, stroke
or death over the ensuing 3 year period. An age and gender matched control
group was randomly selected from GeneBank subjects that did not experience a
CVD event. An independent non overlapping Validation Cohort (N 25 cases
and 25 controls) was also fromGeneBank. A third large (N 1,876) independent
study comprised of non overlapping subjects then evaluated clinical associations
of identified analytes. Approximately half (N 1,020) of the subjects enrolled
were from GeneBank and the remaining (N 856) were from BioBank. Similar
patient characteristics within each cohort and the combined cohort are observed,
as shown in Supplementary Table 4a, b. The association of each PC metabolite
and various cardiovascular phenotypes within each cohort (GeneBank and
BioBank) are also similar (Supplementary Tables 4c e). All subjects in the large
independent clinical study had similar inclusion and exclusion criterion, negative
cardiac enzymes (troponin I, 0.03 ngml 1) and no recent history of myocardial
infarction or coronary artery bypass graft. Estimate of glomerular filtration ratewas
calculated using the MDRD formula46. Fasting blood glucose, C reactive protein,
troponin I and lipid profiles were measured on the Abbott ARCHITECT platform
(Abbott Diagnostics).
Metabolomics analyses. Plasma proteins were precipitated with four volumes of
ice cold methanol and small molecule analytes within supernatants were ana
lysed after injection onto a phenyl column (4.63 250mm, 5 mm Rexchrom
Phenyl; Regis) at a flow rate of 0.8mlmin 1 using a Cohesive HPLC interfaced
with a PE Sciex API 365 triple quadrupole mass spectrometer (Applied
Biosystems) with Ionics HSID1, EP101, XT1 redesigned source and collision
cell as upgrades in positive MS1 mode. LC gradient (LC1) starting from 10mM
ammonium formate over 0.5min, then to 5mM ammonium formate, 25%meth
anol and 0.1% formic acid over 3min, held for 8min, followed by 100%methanol
and water washing for 3min at a flow rate of 0.8mlmin 1 was used to resolve
analytes. Spectra were continuously acquired after the initial 4min. Peaks within
reconstructed ion chromatograms at 1 AMU increments were integrated and both
retention times and m/z of analytes were used for statistical analyses.
Selection criteria for determining analytes of interest were based on the com
posite of MACE as the clinical phenotype, defined as incident myocardial infarc
tion, stroke or death at 3 years, and included: (1) demonstration of a statistically
significant difference between cases versus controls using a Bonferroni adjusted
two sided t test (P, 0.05); (2) evidence of a significant (P, 0.05) dose response
relationship between analyte level and clinical phenotype using Cochran
Armitage trend test; and (3) a minimal signal to noise ratio of 5:1 for a given
analyte.
Chemical characterization of unknown metabolites. To chemically define the
structures of the plasma analytes selected for further investigation (that is, ana
lytes withm/z 76, 104 and 118 in positive MS1 mode), multiple approaches were
used. Analytes of interest were isolated by HPLC, vacuum dried, re dissolved in
water and injected onto the same phenyl column with a distinct HPLC gradient
(LC2, flow rate: 0.8mlmin 1) starting from 0.2% formic acid over 2min, then
linearly to 18% acetonitrile containing 0.2% formic acid over 18min and further
to 100% acetonitrile containing 0.2% formic acid over 3min. The targeted ana
lytes were identified by their m/z and the appropriate fractions recovered. After
removal of solvent, dry analytes were used for structural identification.
Samples analysed by GC/MS were derivatized using Sylon HTP kit (HMDS1
TMCS 1 Pyridine (3: 1: 9), Supelco). Derivatization of TMAO and the plasma
analyte at m/z 76 also included initial reduction by titanium (III) chloride47 and
further reaction with 2,2,2 trichloroethylchloroformate48. Analyses were per
formed on the Agilent Technolgies 6890/5973 GC/MS in positive ion chemical
ionizationmode. TheGC/MS analyses used a J&WScientificDB 1 column (30m,
0.25 mm inner diameter, 0.25 mm film thickness) for separations.
Quantification of TMAO, choline and betaine. Stable isotope dilution LC/MS/
MS was used for quantification of TMAO, choline and betaine. TMAO, choline
and betaine were monitored in positive MRM MS mode using characteristic
precursor product ion transitions: m/z 76R 58, m/z 104R 60 and m/z
118R 59, respectively. The internal standards TMAO trimethyl d9 (d9
TMAO) and choline trimethyl d9 (d9 choline), were added to plasma samples
before protein precipitation, and were similarly monitored in MRMmode atm/z
85R 68 andm/z 113R 69, respectively. Various concentrations of TMAO, cho
line and betaine standards and a fixed amount of internal standards were spiked
into control plasma to prepare the calibration curves for quantification of plasma
analytes. TMA was similarly quantified from acidified plasma by LC/MS/MS
using MRM mode.
Aortic root lesion quantification. Apolipoprotein E knockout mice (C57BL/6J
Apoe2/2) were weaned at 4 weeks of age and fed with either standard chow
control diet (Teklad 2018) or a custom diet comprised of normal chow supple
mented with 0.5% choline (Teklad TD.07863), 1.0% choline (Teklad TD.07864)
or 0.12% TMAO (Teklad TD.07865) for 16 weeks. Mice were anaesthetized with
ketamine/xylazine before cardiac puncture to collect blood.Hearts were fixed and
stored in 4% paraformaldehyde before frozen OCT sectioning and staining with
Oil red O and haematoxylin. Aortic root lesion area was quantified as the mean
value of six sections39. Aortic sections were immunostained with rat anti mouse
F4/80 antibody (ab6640, Abcam) followed by goat anti rat IgG FITC antibody
(sc 2011, Santa Cruz) and FITC conjugated CD36 monoclonal antibody
(Cayman Chemical) for F4/80 and CD36, respectively. Sections were mounted
in Vectashield DAPI (H 1200, Vectashield) to take pictures under a Leica DMR
microscope (W. Nuhsbaum) equipped with a Q Imaging Retiga EX camera. We
used Image Pro Plus Version 7.0 (MediaCybernetics) to integrate the positive
staining area of F4/80 and CD36 in aorta.
Flow cytometry assays on scavenger receptors. Cell surface expression of
scavenger receptors SR A1 andCD36were quantified on peritonealmacrophages
from female mice by flow cytometry after immunostaining with fluorochrome
conjugated antibodies. Fluorescence intensity was quantified on a FACSCalibur
flow cytometry instrument with FlowJo software (BD Biosciences). More than
10,000 total events were acquired to obtain adequate macrophages numbers.
The following antibodies were used to stain macrophages: CD36 monoclonal
antibody FITC (Cayman Chemical), anti mouse SR AI/MSRA1 (R&D Systems),
goat anti rat IgG FITC (Santa Cruz Biotechnology), Alexa Fluor 647 anti mouse
F4/80 (eBioscience), Alexa Fluor 647 anti mouse CD11b (eBioscience) and the
isotype controls, Alexa Fluor 647 rat IgG2b (eBioscience), Alexa Fluor 647 rat
IgG2a (eBioscience), normal mouse IgA FITC (Santa Cruz). Cells were incubated
with antibodies for 30 min at 4uC and washed with 0.1% BSA in PBS. Cells with
double positive staining for F4/80 and CD11b were gated as macrophage49 51 for
the quantification of fluorescence intensity for CD36 and SR A1 (Supplementary
Fig. 20), with results normalized to F4/80.
eQTL studies. C57BL/6J Apoe / (B6 Apoe / ) mice were purchased from the
Jackson Laboratory and C3H/HeJ Apoe / (C3H Apoe / ) mice were bred by
backcrossing B6Apoe / to C3H/HeJ for 10 generations. F2mice were generated
by crossing B6 Apoe / with C3H Apoe / and subsequently intercrossing the
F1 mice. Mice were fed Purina Chow containing 4% fat until 8 weeks of age, and
then transferred to a Western diet (Teklad 88137) containing 42% fat and 0.15%
cholesterol for 16 weeks until euthanasia at 24 weeks of age. Mouse atherosclerotic
lesion area was quantified using standard methods39. eQTL analyses were per
formed as previously described38. Each individual sample was hybridized against
the pool of F2 samples. Significantly differentially expressed geneswere determined
as previously described52. Expression data in the form ofmean log ratios (mlratios)
were treated as a quantitative trait in eQTL analysis using Rqtl package for the R
language and environment for statistical computing (http://cran.r project.org/).
Germ free mice and conventionalization studies. An antibiotic cocktail
(0.5 g l 1 vancomycin, 1 g l 1 neomycin sulphate, 1 g l 1 metronidazole, 1 g l 1
ampicillin) previously shown to be sufficient to deplete all detectable commensal
bacteria37 was administered in drinking water ad libitum. In additional studies,
8 week old female SwissWebster germ freemice (Taconic SWGF) underwent an
oral (gavage) choline challenge (see later) immediately after their removal from
their germ free microisolator shipper. After the choline or PC challenge, the
germ free mice were placed in conventional cages with non sterile C57BL/6J
female mice to facilitate transfer of commensal organisms. Four weeks later,
the conventionalized mice underwent a second choline or PC challenge.
In vivo macrophage studies. C57BL/6J mice or B6 Apoe / mice were fed with
either standard chow control diet (Teklad 2018) or a custom diet supplemented
with 1.0% betaine (Teklad TD.08112), 1.0% choline (Teklad TD.07864), 0.12%
TMAO (Teklad TD.07865) or 1.0% dimethylbutanol (DMB) supplemented in
drinking water for at least 3 weeks. Elicited mouse peritoneal macrophages
(MPMs) were harvested by peritoneal lavage with ice cold PBS 3 days after i.p.
injection of 1ml 4% thioglycollate. Some studies withmicewere performedusing a
customdietwith lowbut sufficient choline content (0.07% total; TekladTD.09040)
versus high choline diet (1.0% total; Teklad TD.09041) in the presence or absence
of antibiotics. Choline content of all diets was confirmed by LC/MS/MS.
Foam cell staining. Foam cells were identified by microscopy cultured peritoneal
macrophages on glass coverslips after 6 h in RPMI 1640 medium supplemented
with 3% lipoprotein deficient serum. Cells were fixed with paraformaldehyde and
stained with Oil red O/haematoxylin53. Cells containing .10 lipid droplets were
scored as foam cells50. At least 10 fields and 500 cells per condition were counted.
Real time PCR. Real time PCR of Cd36, Sr a1 and flavin monooxygenases
(mouse Fmos) was performed using Brilliant II SYBR Green qRT PCR kit
(Strategene). The forward and reverse primers Cd36, Gapdh, Sr a1, mouse Fmos
and F4/80 were synthesized by IDT based on sequences reported54 58. RT PCR of
human FMOs was similarly performed using primers specific for the sequence of
each of the indicated human FMOs.
d9 DPPC synthesis and vesicle preparation. d9 DPPCwas synthesized by react
ing 1,2 dipalmitoyl sn glycero 3 phosphoethanolamine (Genzyme Pharmaceuticals)
withper deuteromethyliodide(CD3I,CambridgeIsotopeLaboratories)59,60.Theproduct
waspurifiedbypreparativesilicagelTLCandconfirmedbybothMSandNMR.Eggyolk
lecithin (Avanti Polar Lipids) and d9 DPPC liposomes used for gavage feeding and i.p.
injection of mice were prepared by the method of extrusion through polycarbonate
filters61.
Metabolic challenges in mice. C57BL/6J mice were administered (gavage)
unlabelled or the indicated stable isotope labelled choline or PC (egg yolk lecithin
or d9 DPPC) using a 1.5 inch 20 gauge intubation needle. Choline challenge:
gavage consisted of 150ml of 150mM d9 choline. PC challenge: gavage or i.p.
injection of 300 ml 5mgml 1 of unlabelled PC or labelled d9 DPPC. Mice were
fasted 12 h before PC challenge. Plasma (50ml) was collected via the saphenous
vein from mice at baseline and after gavage or i.p. injection time points.
Statistical analysis. Student’s t test andWilcoxon rank sum test were employed to
compare group means62,63. Pearson correlation, Spearman rank correlation and
Somers’ Dxy correlation were used to investigate the correlation between two
variables64,65. Comparison of categorical measures between independent groups
was done using x2 tests66. Odds ratios and 95% confidence intervals for cardio
vascular phenotypes (history of myocardial infarction, CAD, PAD, CVD and
CAD1PAD) were calculated with R, version 2.10.1 (http://www.r project.org),
using logistic regression67 with case status as the dependent variable and plasma
analyte as independent variable. Trend tests in frequencies across quartiles were
done using Cochran Armitage trend tests68. Levels of analytes were adjusted for
traditional CAD risk factors in a multivariate logistic regression model including
individual traditional cardiac risk factors (age, gender, diabetes, smoking, hyper
tension, lipids, CRP and estimated creatinine clearance) and medication usage
(statin or other lipid lowering agents, antihypertensive agents including angioten
sin converting enzyme inhibitor, angiotensin receptor blocking agent, diuretic,
calcium channel blocker or beta blocker, and aspirin or other platelet inhibitors).
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